SCHEMBL6690903

SCHEMBL6690903

CC(C)(C)OC(=O)N(Cc1ccc(C(=O)N[C@@H](CCCNCc2ccc[nH]2)C(=O)O)cc1)Cc1ccccn1.NCc1cccc2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.41
FNTA P49354 3/20 0.38
FNTB P49356 3/20 0.38
HDAC1 Q13547 3/20 0.37
HDAC3 O15379 2/20 0.37
HDAC2 Q92769 2/20 0.37
NCOR2 Q9Y618 2/20 0.37
FOLH1 Q04609 1/20 0.36
BACE1 P56817 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CASR P41180 1/20 0.33
DHFR P00374 4/20 0.32
FPGS Q05932 2/20 0.32
TYMS P04818 1/20 0.32
PGGT1B P53609 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
TPSAB1 Q15661 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018348 0.91 HDAC1 (0.35) CXCR4FNTAFNTBHDAC1HDAC3
SCHEMBL6689236 0.87 CXCR4 (0.40) CXCR4FNTAFNTBHDAC1HDAC3
SCHEMBL6018874 0.87 CXCR4 (0.39) CXCR4FNTAFNTBHDAC1HDAC3
SCHEMBL6019678 0.87 CXCR4 (0.46) CXCR4FNTAFNTBHDAC1HDAC3
SCHEMBL6018470 0.86 CXCR4 (0.51) CXCR4FNTAFNTBHDAC1FOLH1
SCHEMBL6685494 0.85 CXCR4 (0.45) CXCR4FNTAFNTBHDAC1FOLH1
SCHEMBL6018441 0.84 CXCR4 (0.36) CXCR4FNTAFNTBHDAC1HDAC3
SCHEMBL6018196 0.84 CXCR4 (0.43) CXCR4FNTAFNTBHDAC1HDAC3
SCHEMBL6019453 0.80 HDAC3 (0.47) CXCR4HDAC1HDAC3HDAC2NCOR2
SCHEMBL6018171 0.80 HDAC1 (0.35) CXCR4FNTAFNTBHDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound KUREHA CORPORATION (JP) 2004-08-12 US disclosed
EP-1389460-A1 CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND Kureha Chemical Industry Co., Ltd. (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound CXCR4, CXCR1, CXCR2 CXCR4 1/4885FNTA 3116/4885FNTB 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.